Shocking bladder trouble away: nerve zap trial for spinal injury patients

NCT ID NCT03965299

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily 30-minute nerve stimulation (TTNS) can prevent bladder overactivity that can damage kidneys after spinal cord injury. 114 patients with acute spinal injury will receive either real or sham stimulation for 6-9 weeks. The goal is to see if the treatment reduces dangerous bladder pressure and the need for medications or Botox injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
transcutaneous tibial nerve stimulation (TTNS) device
What this could lead to
If it works, this could offer a non-invasive way to prevent serious bladder damage after spinal cord injury, reducing the need for medications or injections.
What could go wrong
This is a mid-sized trial testing a prevention approach; the effect may be small or not work for everyone. The treatment requires daily sessions for weeks, which may be burdensome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Neuro-Urology, Spinal Cord Injury Centre & Research, Balgrist University Hospital

    RECRUITING

    Zurich, Canton of Zurich, 8008, Switzerland

  • REHAB Basel

    RECRUITING

    Basel, Switzerland

  • Spinal Cord Injury Department, Clinique romande de réadaption

    RECRUITING

    Sion, Switzerland

  • Swiss Paraplegic Centre

    RECRUITING

    Nottwil, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.